Arcutis Biotherapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151...
Latest News
3 days ago · globenewswire.com
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific MeetingNew INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families Findings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to
12 days ago · globenewswire.com
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic DermatitisNew INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment to individuals with moderate to severe atopic dermatitis Builds on existing evidence of ZORYVE cream 0.15% for individuals ages 6 and older and ZORYVE cream 0.05% for children ages 2 to 5 with mild to moderate atopic dermatitis WESTLAKE VILLAGE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 3, double-blind, randomized, vehicle-controlled study, INTEGUMENT-3.
12 days ago · seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call TranscriptArcutis Biotherapeutics, Inc. ( ARQT ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian Schoelkopf - Head of Investor Relations Todd Watanabe - President, CEO & Director Robert Lisicki - Interim Executive VP & Chief Commercial Officer Patrick Burnett - Executive VP & Chief Medical Officer Latha Vairavan - Senior VP & Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Lin Tsai - Jefferies LLC, Research Division Ikenna Okafor - TD Cowen, Research Division Parth Patel - Morgan Stanley, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division John Gionco - Needham & Company, LLC, Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
12 days ago · marketbeat.com
Arcutis Biotherapeutics Q3 Earnings Call HighlightsArcutis Biotherapeutics NASDAQ: ARQT raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand.
12 days ago · zacks.com
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings EstimatesArcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.06 per share a year ago.
20 days ago · zacks.com
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthArcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
20 days ago · globenewswire.com
Arcutis Appoints Rob Scott, MD to Board of DirectorsRob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.
20 days ago · globenewswire.com
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceWESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.
26 days ago · globenewswire.com
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026Arcutis today announced that it will report its Q3 2026 financial results and provide a business update after the U.S. financial markets close on Nov 4.
1 month ago · benzinga.com
Why Is Arcutis Biotherapeutics Stock Surging Thursday?Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales growth and expansion opportunities in dermatology.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ARQT